FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224324555> ?p ?o ?g. }

• W4224324555 abstract "Abstract Background/Aims The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area and Severity Index (PASI) 100 responses. To minimize confounding effects, in this analysis we assessed the efficacy of either IXE or ADA monotherapy on reduction of pain beyond measurable inflammation in patients with active PsA and low C-reactive protein (CRP) (&lt;5mg/L) at baseline. Methods SPIRIT-H2H (NCT03151551) was a 52 week (W), multicenter, randomized, open-label, parallel-group, assessor-blinded study evaluating the efficacy and safety of IXE vs ADA. Participants were randomized (1:1) to approved-label dosing of IXE or ADA. This post-hoc analysis included only patients treated with IXE or ADA as monotherapy and with low CRP (&lt;5mg/L) at baseline. Changes in joint pain were measured using PsA Patient’s Assessment of Pain Visual Analog Scale (VAS). We stratified patients into four categories by two measures of inflammation: 1. Sustained low inflammation either by a. CRP&lt;5 mg/L during W4-24 or b. ≥50% improvement in swollen joint count (SJC) during W8-24. 2. Fluctuating inflammation either by a. CRP≥5 mg/L at least once between W4-24 or &lt; 50% improvement in SJC at least once between W8-24. Results 95 monotherapy patients with a CRP &lt;5mg/L at baseline were included in this analysis. Baseline characteristics were similar between both treatment arms. In patients with fluctuating inflammation as measured by CRP, IXE-treated patients demonstrated a numerically greater mean improvement in joint pain VAS vs ADA-treated patients at W16 (IXE: -31.64, ADA: -25.33) that was sustained up to W52 (IXE: -47.69, ADA: -20.67). There was significance in favor of IXE at W32 (p = 0.0045) and W52 (p = 0.0288). In patients with sustained low inflammation as measured by CRP, there was comparable improvement in joint pain between IXE and ADA-treated patients. In patients with sustained improvement in joint swelling as assessed by SJC, IXE-treated patients demonstrated a numerically greater mean improvement in joint pain VAS vs ADA-treated patients from W4 (IXE: -17.47, ADA: -10.42) that was sustained through W52 (IXE: -43.16, ADA: -32.62). In patients with fluctuating improvement in joint swelling as assessed by SJC, IXE-treated patients demonstrated a numerically greater mean improvement in joint pain VAS vs ADA-treated patients from W16 (IXE: -22.00, ADA: -19.31) that was sustained through W52 (IXE: -28.57, ADA: -13.27). Conclusion This analysis suggests a different pattern of pain improvement in patients with low baseline CRP treated with IXE or ADA monotherapy, with a favorable pain reduction outcome for IXE-treated patients, even when inflammation is fluctuating as measured by CRP or SJC improvement. This analysis supports the hypothesis that IXE improves joint pain in PsA patients with and without measurable inflammation. Disclosure N. Maney: None. K. de Vlam: Consultancies; Celgene, Eli Lilly and Company, Galapagos NV, Novartis, Pfizer, and UCB Pharma. Grants/research support; Celgene. G. Gallo: Shareholder/stock ownership; Eli Lilly and Company. P. Mease: Consultancies; AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Galapagos NV, Gilead Sciences, GlaxoSmithKline. Member of speakers’ bureau; AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB Pharma. Grants/research support; Janssen, Merck Sharp & Dohme, Neumentum, Novartis, Pfizer, Sun Pharma, and UCB Pharma. P. Rahman: Consultancies; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and UCB Pharma. Grants/research support; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and UCB Pharma. V. Krishnan: Shareholder/stock ownership; Eli Lilly and Company. D. Sandoval Calderon: Shareholder/stock ownership; Eli Lilly and Company. C. Lin: Shareholder/stock ownership; Eli Lilly and Company. D. Zhu: Shareholder/stock ownership; Eli Lilly and Company. R. Bolce: Shareholder/stock ownership; Eli Lilly and Company. P. Conaghan: Consultancies; Amgen, Bristol Myers Squibb, Eli Lilly and Company, Galapagos NV, Gilead Sciences, Novartis, Pfizer, and UCB Pharma." @default.
• W4224324555 created "2022-04-26" @default.
• W4224324555 creator A5004498996 @default.
• W4224324555 creator A5020923397 @default.
• W4224324555 creator A5034369585 @default.
• W4224324555 creator A5034564939 @default.
• W4224324555 creator A5053254718 @default.
• W4224324555 creator A5066580060 @default.
• W4224324555 creator A5079197692 @default.
• W4224324555 creator A5081778211 @default.
• W4224324555 creator A5087471106 @default.
• W4224324555 creator A5087638936 @default.
• W4224324555 creator A5089966781 @default.
• W4224324555 date "2022-04-23" @default.
• W4224324555 modified "2023-10-18" @default.
• W4224324555 title "P276 Ixekizumab shows a pattern of pain improvement in patients with and without measurable inflammation in psoriatic arthritis" @default.
• W4224324555 doi "https://doi.org/10.1093/rheumatology/keac133.275" @default.
• W4224324555 hasPublicationYear "2022" @default.
• W4224324555 type Work @default.
• W4224324555 citedByCount "0" @default.
• W4224324555 crossrefType "journal-article" @default.
• W4224324555 hasAuthorship W4224324555A5004498996 @default.
• W4224324555 hasAuthorship W4224324555A5020923397 @default.
• W4224324555 hasAuthorship W4224324555A5034369585 @default.
• W4224324555 hasAuthorship W4224324555A5034564939 @default.
• W4224324555 hasAuthorship W4224324555A5053254718 @default.
• W4224324555 hasAuthorship W4224324555A5066580060 @default.
• W4224324555 hasAuthorship W4224324555A5079197692 @default.
• W4224324555 hasAuthorship W4224324555A5081778211 @default.
• W4224324555 hasAuthorship W4224324555A5087471106 @default.
• W4224324555 hasAuthorship W4224324555A5087638936 @default.
• W4224324555 hasAuthorship W4224324555A5089966781 @default.
• W4224324555 hasBestOaLocation W42243245551 @default.
• W4224324555 hasConcept C126322002 @default.
• W4224324555 hasConcept C14184104 @default.
• W4224324555 hasConcept C142724271 @default.
• W4224324555 hasConcept C16005928 @default.
• W4224324555 hasConcept C1862650 @default.
• W4224324555 hasConcept C204787440 @default.
• W4224324555 hasConcept C27081682 @default.
• W4224324555 hasConcept C2776252253 @default.
• W4224324555 hasConcept C2776260265 @default.
• W4224324555 hasConcept C2776914184 @default.
• W4224324555 hasConcept C2777011040 @default.
• W4224324555 hasConcept C2777077863 @default.
• W4224324555 hasConcept C2777575956 @default.
• W4224324555 hasConcept C2779745271 @default.
• W4224324555 hasConcept C2779786854 @default.
• W4224324555 hasConcept C2780132546 @default.
• W4224324555 hasConcept C2780564577 @default.
• W4224324555 hasConcept C67761136 @default.
• W4224324555 hasConcept C71924100 @default.
• W4224324555 hasConceptScore W4224324555C126322002 @default.
• W4224324555 hasConceptScore W4224324555C14184104 @default.
• W4224324555 hasConceptScore W4224324555C142724271 @default.
• W4224324555 hasConceptScore W4224324555C16005928 @default.
• W4224324555 hasConceptScore W4224324555C1862650 @default.
• W4224324555 hasConceptScore W4224324555C204787440 @default.
• W4224324555 hasConceptScore W4224324555C27081682 @default.
• W4224324555 hasConceptScore W4224324555C2776252253 @default.
• W4224324555 hasConceptScore W4224324555C2776260265 @default.
• W4224324555 hasConceptScore W4224324555C2776914184 @default.
• W4224324555 hasConceptScore W4224324555C2777011040 @default.
• W4224324555 hasConceptScore W4224324555C2777077863 @default.
• W4224324555 hasConceptScore W4224324555C2777575956 @default.
• W4224324555 hasConceptScore W4224324555C2779745271 @default.
• W4224324555 hasConceptScore W4224324555C2779786854 @default.
• W4224324555 hasConceptScore W4224324555C2780132546 @default.
• W4224324555 hasConceptScore W4224324555C2780564577 @default.
• W4224324555 hasConceptScore W4224324555C67761136 @default.
• W4224324555 hasConceptScore W4224324555C71924100 @default.
• W4224324555 hasIssue "Supplement_1" @default.
• W4224324555 hasLocation W42243245551 @default.
• W4224324555 hasOpenAccess W4224324555 @default.
• W4224324555 hasPrimaryLocation W42243245551 @default.
• W4224324555 hasRelatedWork W1877047792 @default.
• W4224324555 hasRelatedWork W2075066605 @default.
• W4224324555 hasRelatedWork W2133696182 @default.
• W4224324555 hasRelatedWork W2162870695 @default.
• W4224324555 hasRelatedWork W2235471063 @default.
• W4224324555 hasRelatedWork W2342884636 @default.
• W4224324555 hasRelatedWork W3035607543 @default.
• W4224324555 hasRelatedWork W3106721720 @default.
• W4224324555 hasRelatedWork W3208988466 @default.
• W4224324555 hasRelatedWork W4224324555 @default.
• W4224324555 hasVolume "61" @default.
• W4224324555 isParatext "false" @default.
• W4224324555 isRetracted "false" @default.
• W4224324555 workType "article" @default.